About Index Trending news
Analyze
Pricing
Delinia

Delinia

Work at Delinia? Add yourself to this profile

Delinia

Delinia aims to discover and develop novel therapeutics targeting regulatory T cells for the treatment of autoimmune and inflammatory diseases
Edit Profile
More info

Elsewhere

Also headquartered in Cambridge

MIT MIT Raspberry Pi Raspberry Pi ARM ARM Xconomy Xconomy Mobile.co Mobile.co nuTonomy nuTonomy HubSpot HubSpot Biogen Biogen General Catalyst General Catalyst Harvard University Harvard University

Companies in the same industry

Mast Therapeutics, Inc. Mast Therapeutics, Inc. BioCision BioCision Diomics Diomics Vasopharm Vasopharm Cofactor Genomics Cofactor Genomics Cariloop Cariloop GlassesOff GlassesOff InPulse Medical InPulse Medical Molecular Imaging Molecular Imaging Izun Pharmaceuticals Izun Pharmaceuticals

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 1
Add info
14 Sep 2016
$35,000,000
Venture capital (Series A)
Atlas Venture, Sofinnova Partners

Delinia Announces $35 Million Series A Financing to Advance Novel Therapeutics Targeting Regulatory T Cells for Autoimmune Diseases | Business Wire

businesswire
+1